Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06270576 · ClinicalTrials.gov registry record · Phase 1
Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma
A Phase 1 study, sponsored by National Jewish Health.
- Not yet
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT06270576 is a Phase 1 study that has not yet begun recruiting, run by National Jewish Health. The registered enrollment target is 60 participants.
The verdict
NCT06270576, a Phase 1 study, has not yet begun recruiting, sponsored by National Jewish Health.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.
Interventions
- DRUG Lipopolysaccharides
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-04 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06270576
The ClinicalTrials.gov registry entry for NCT06270576 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lipopolysaccharides is the first listed.
NCT06270576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06270576 about?
NCT06270576 is a clinical study titled "Nasal Inflammation Following Endotoxin Challenge in Patients With Asthma". A phase I clinical research study aimed at determining mechanisms that regulate airway mucosal inflammation in asthma endotypes using intranasal administration of endotoxin (lipopolysaccharide from E. coli) in healthy controls and subjects diagnosed with asthma.
What is the current status of trial NCT06270576?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-04. Estimated completion is 2028-06.
What interventions are being tested in trial NCT06270576?
The interventions under investigation include: Lipopolysaccharides (DRUG).
Who is sponsoring clinical trial NCT06270576?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.